MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG

Alcon to develop SMART Suite digital health platform for cataract surgery

- **SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients**
- **As an open, secure cloud-enabled ecosystem, SMART Suite by Alcon will bring greater efficiency to the cataract surgical process and help optimize outcomes for patients**
- **SMART Suite by Alcon is built on the Philips HealthSuite platform, a proven design which accelerates digital health innovation in eye care**

**Fort Worth, Texas (October 23, 2018)** -- Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients.

The SMART Suite by Alcon will connect multiple diagnostic and surgical devices through a digital, open cloud-based infrastructure that seamlessly integrates with practices’ existing cataract diagnostic equipment, electronic medical record (EMR) systems, and technologies in the Alcon Cataract Refractive Suite. As envisioned, eye care professionals will have easy access to patients’ vital diagnostic data throughout the cataract procedure, providing a simplified clinical process, consistency and greater efficiency. The cloud-based data will help eye care professionals analyze and optimize procedures with increased precision, driving improved patient outcomes.

“The SMART Suite by Alcon will be an important addition to our market-leading cataract refractive equipment portfolio and it builds on our existing cloud-based technologies like the ORA System,” said Michael Onuscheck, President, Global Business & Innovation at Alcon. “Our collaboration with Philips reflects our ongoing commitment to deliver market-leading innovations that improve the surgical process and deliver optimal outcomes for patients.”

The SMART Suite by Alcon will be built on the Philips HealthSuite digital platform, which provides the proven expertise and regulatory compliance for cloud-based services and technical tools that will enable SMART Suite to fit seamlessly into customers’ practices. HealthSuite’s medical cloud capabilities will connect Alcon and third party surgical and diagnostic devices, while its data aggregation and storage services will allow eye care professionals to collect data from devices, EMRs and patients and store it securely. The identity and access management capabilities are designed to safeguard the privacy of health data by controlling administrator, as well as patient and clinician access to data. In addition, the Philips platform will enable the SMART Suite by Alcon to facilitate secure, open data exchange between facilities, clinicians and patients.
“We are excited to facilitate the global shift of eye care professionals and the eye care industry to connected health,” said Dale Wiggins, Business Leader HealthSuite digital platform at Philips. “The ability of Philips’ HealthSuite digital platform to securely unify and connect devices and data while providing advanced analytics capabilities is a powerful tool for the next generation of personalized eye care solutions.”

Alcon plans to announce additional details on the SMART Suite in mid-2019. The SMART Suite will be fully compatible with currently available surgical equipment, including Centurion, ORA, Verion, LenSx and other planned future additions to the Alcon Cataract Refractive Suite.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “to develop,” “potential,” “can,” “will,” “plans,” “planned,” “expect,” “look forward,” “believe,” “commitment,” “investigational,” “launch,” or similar terms, or by expressed or implied discussions regarding potential marketing approvals or clearances, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted, approved or cleared for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that the agreement with Philips will achieve any or all of its intended goals and objectives, or be commercially successful. Nor can there be any guarantee that the products described in this press release will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular purchasing and prescribing preferences of physicians; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Alcon
Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our products touch the
lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Learn more at www.alcon.com.

Alcon is on Facebook. Like us at www.facebook.com/AlconEyeCare.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis. For Novartis multimedia content, please visit www.novartis.com/news/media-library. For questions about the site or required registration, please contact media.relations@novartis.com

# # #

Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.com

Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com

Steven Smith Alcon Global Communications +1 817 551 8211 (direct) +1 213 280 9974 (mobile) steven_p.smith@alcon.com

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Central  North America
Samir Shah Richard Pulik +41 61 324 7944 +1 212 830 2448 Pierre-Michel Bringer Cory Twining +41 61 324 1065 +1 212 830 2417 Thomas Hungerbuehler Isabella Zinck +41 61 324 8425 +41 61 324 7188